TY - JOUR
T1 - Toward personalized medicine of lung cancer
T2 - Response to nontargeted therapy in invasive pulmonary adenocarcinoma as a function of tumor cell differentiation
AU - Hartel, Paul H.
AU - Hartel, James V.
AU - Fanburg-Smith, Julie C.
AU - Gilmore, R. Wayde
AU - Fleming, Donald
AU - Barnett, Steve
AU - Mudry, Ronald
AU - Parker, John E.
PY - 2013/6
Y1 - 2013/6
N2 - We evaluated clinical parameters, histomorphology, and thyroid transcription factor 1 (TTF-1) immunoreactivity in 40 epidermal growth factor receptor (EGFR) mutation- and anaplastic lymphoma kinase (ALK) rearrangement-negative invasive pulmonary adenocarcinomas. Tumors were histomorphologically quantitated by a pulmonary pathologist and TTF-1 immunohistochemistry applied. EGFR mutation and ALK rearrangement status was determined with polymerase chain reaction/DNA sequencing and fluorescence in situ hybridization, respectively. Treatment response was related to type of treatment (P <.005) and clinical stage (P =.001). EGFR mutation- and ALK rearrangement-negative pulmonary adenocarcinomas containing papillary/ micropapillary histology showed greater morphologic heterogeneity (P <.001), greater TTF-1 immunoreactivity (P =.004), and were more common in treatment responders (P <.05). These findings support that patients with pulmonary adenocarcinomas that are subject to nontargeted therapies may respond to treatment as a function of tumor cell differentiation with TTF-1 as a potential biomarker of this response.
AB - We evaluated clinical parameters, histomorphology, and thyroid transcription factor 1 (TTF-1) immunoreactivity in 40 epidermal growth factor receptor (EGFR) mutation- and anaplastic lymphoma kinase (ALK) rearrangement-negative invasive pulmonary adenocarcinomas. Tumors were histomorphologically quantitated by a pulmonary pathologist and TTF-1 immunohistochemistry applied. EGFR mutation and ALK rearrangement status was determined with polymerase chain reaction/DNA sequencing and fluorescence in situ hybridization, respectively. Treatment response was related to type of treatment (P <.005) and clinical stage (P =.001). EGFR mutation- and ALK rearrangement-negative pulmonary adenocarcinomas containing papillary/ micropapillary histology showed greater morphologic heterogeneity (P <.001), greater TTF-1 immunoreactivity (P =.004), and were more common in treatment responders (P <.05). These findings support that patients with pulmonary adenocarcinomas that are subject to nontargeted therapies may respond to treatment as a function of tumor cell differentiation with TTF-1 as a potential biomarker of this response.
UR - http://www.scopus.com/inward/record.url?scp=84878226873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878226873&partnerID=8YFLogxK
U2 - 10.1177/1066896913486694
DO - 10.1177/1066896913486694
M3 - Article
C2 - 23637254
AN - SCOPUS:84878226873
SN - 1066-8969
VL - 21
SP - 224
EP - 228
JO - International Journal of Surgical Pathology
JF - International Journal of Surgical Pathology
IS - 3
ER -
